Louise C. Brown

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Journal: The Journal of clinical investigation

Published: March 31, 2026

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Journal: The Journal of clinical investigation

Published: March 31, 2026

Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.

Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.

Journal: The New England journal of medicine

Published: March 25, 2026

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 06, 2026

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 06, 2026

Facilitating access to clinical data from a randomized controlled trial of complex adaptive design.

Facilitating access to clinical data from a randomized controlled trial of complex adaptive design.

Journal: BMC research notes

Published: December 22, 2025

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

Journal: The Lancet. Oncology

Published: November 05, 2025

Quantification of Abdominal Aortic Calcification on CT: Clinical Validation for Assessment Of Cardiovascular Risk in Oncology.

Quantification of Abdominal Aortic Calcification on CT: Clinical Validation for Assessment Of Cardiovascular Risk in Oncology.

Journal: Journal of imaging informatics in medicine

Published: September 22, 2025

Integrating Social Care into Pharmacy Interprofessional Education Through Holistic Collaborative Learning.

Integrating Social Care into Pharmacy Interprofessional Education Through Holistic Collaborative Learning.

Journal: American journal of pharmaceutical education

Published: April 24, 2025

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Journal: The Lancet. Oncology

Published: March 13, 2025

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 10, 2025

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 27, 2025

Showing 1-12 of 88

Last Updated: 09/26/2026